Mei Ri Jing Ji Xin Wen·2025-09-29 14:00Core Viewpoint - White Cloud Mountain and Nanjing Pharmaceutical have signed a strategic investment agreement, where White Cloud Mountain's Guangzhou Traditional Chinese Medicine Phase II Fund will acquire 11.04% of Nanjing Pharmaceutical's shares, becoming its second-largest shareholder [1][2] Group 1: Strategic Investment Details - The acquisition involves 144 million non-restricted shares at a price of 5.18 yuan per share, totaling an investment of 749 million yuan [1][2] - The agreement is part of White Cloud Mountain's new leadership strategy and aims to enhance cooperation with regional industry leaders [1][2] - The acquisition requires approval from the state-owned assets regulatory authority and compliance review by the Shanghai Stock Exchange [2] Group 2: Company Background and Financials - Nanjing Pharmaceutical's major shareholder is Nanjing New Industry Investment Group, holding 44.17% of shares, while the remaining shareholders have less than 3% each [2] - Nanjing Pharmaceutical reported a revenue of 27.967 billion yuan in the first half of the year, a year-on-year increase of 2.70%, but a net profit decline of 6.44% to 291 million yuan [4] - White Cloud Mountain's commercial segment, which includes pharmaceutical distribution, generated 29 billion yuan in revenue, accounting for 54.90% of total revenue [4] Group 3: Industry Trends - The pharmaceutical distribution industry is experiencing significant consolidation, with the top ten companies projected to hold an 82% market share by 2025 [4] - Both White Cloud Mountain and Nanjing Pharmaceutical are key players in the pharmaceutical distribution sector, ranking sixth and seventh respectively in a recent industry report [4]